ALZINOVA Aktie

 

Tord Labuda has entered the role as CEO of Alzinova, bringing extensive experience from leading positions in the pharmaceutical industry. The company is in an exciting development phase, as the clinical phase Ib study with the Alzheimer's vaccine ALZ-101 is expected to be completed in early 2025. In preparation for phase II, Alzinova is actively exploring opportunities for licensing agreements with a larger pharma company. Read the full interview with Tord Labuda at biostock.se: https://www.biostock.se/en/2024/10/alzinovas-new-ceo-the-next-six-months-will-be-really-exciting/ This is a...

Stayble Therapeutics AB announces that Erik Kullgren has been appointed as the new CFO, effective August 1, 2024. Erik Kullgren has an MBA from the School of Economics at the University of Gothenburg and has extensive experience as a CFO for both listed and unlisted companies. He has also been CEO of Reguity Group AB and Dunross & Co AB. Erik Kullgren currently runs his own consulting company where he acts as CFO for, among others, Alzinova AB and Shortcut Media Group.   We welcome Erik as the new CFO of Stayble and look forward to working together. With his solid experience and...

Das Instrument 78D SE0007413455 ALZINOVA AB EQUITY wird ex Kapitalmassnahme gehandelt am 31.05.2024 The instrument 78D SE0007413455 ALZINOVA AB EQUITY is traded ex capital adjustment on 31.05.2024...